COMMUNIQUÉS West-GlobeNewswire

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
24/02/2026
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real ‑ world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple [...]
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
Full-year 2025 net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI ® (pegcetacoplan) full year 2025 net product revenue of $102 million [...]
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
24/02/2026
PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
24/02/2026
“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious [...]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
24/02/2026
― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, [...]
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
24/02/2026
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq [...]
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
24/02/2026
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
24/02/2026
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F- [...]
Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
24/02/2026
2025 net revenues increased 5.7% to $1.164 billion , compared to 2024, or 5.2% on a constant currency basis 2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or [...]
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
24/02/2026
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance [...]
Ocular Therapeutix™ to Participate in March Investor Conferences
24/02/2026
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the [...]
EyePoint Announces Participation at Upcoming Investor Conferences
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
24/02/2026
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients [...]
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
24/02/2026
Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML SAN DIEGO and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aptose [...]
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
24/02/2026
– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 [...]
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
24/02/2026
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact [...]

Pages